ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

Study: Molecular Breast Imaging Can Be As Effective as MRI

July 27, 2012

OMB reviewing Administration’s Reauthorization Bill; NCI Special Authority Probably Will Remain

April 15, 1988

Racial Differences In Survival Increase According To Stage

August 31, 2007

Clinical Study Group Proposed To Examine Peer Review System

October 15, 1993

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

September 28, 2012

Newcomers Undercut Price of BRCA Test; Myriad Lawsuits Claim Patent Infringement

July 25, 2013